Hemolytic uremic syndrome recurrence after renal transplantation.

Abstract	About 60% of non-Stx-associated aHUS are due to the defect of protection of endothelial cells from complement activation, secondary to mutations in the genes of CFH, MCP, IF, BF, or C3. In addition, 10% of patients have anti-CFH antibodies. While the risk of post-transplant recurrence is less than 1% in Stx-HUS patients, it is approximately 80% in CFH or IF-mutated patients, 20% in MCP-mutated patients, and 30% in patients with no mutation. Patients with anti-CFH antibodies probably also are at risk of recurrence. While MCP-mutated patients can reasonably go to transplantation, recent reports suggest that plasmatherapy started before surgery and maintained life-long may prevent recurrence in CFH-mutated patients. Four successful liver-kidney transplantation utilizing plasmatherapy in CFH-mutated children have been reported recently. In summary, the risk of post-transplant recurrence can now be approached according to genotype. Therefore, aHUS patients should undergo complement determination, screening for anti-CFH antibodies, and genotyping before transplantation. Kidney or kidney + liver transplantation with concomitant plasmatherapy need to be evaluated by prospective trials in patients with hereditary complement abnormalities.
Authors	Chantal Loirat, Véronique Fremeaux-Bacchi
Journal	Pediatric transplantation (Pediatr Transplant) Vol. 12 Issue 6 Pg. 619-29 (Sep 2008) ISSN: 1399-3046 [Electronic] Denmark
PMID	18482212 (Publication Type: Journal Article)
Chemical References	Complement C3 Membrane Cofactor Protein Shiga Toxin Complement Factor H Complement C3-C5 Convertases Complement Factor B
Topics	Adult Child, Preschool Complement C3 (biosynthesis) Complement C3-C5 Convertases (metabolism) Complement Factor B (biosynthesis) Complement Factor H (genetics) Hemolytic-Uremic Syndrome (diagnosis, etiology, pathology) Humans Infant Kidney Transplantation (adverse effects) Liver Transplantation (methods) Membrane Cofactor Protein (biosynthesis) Recurrence Shiga Toxin (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!